Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0684249 (
lung carcinoma
)
23,830
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The insulin-receptor substrate family plays important roles in cellular growth, signaling, and survival. Two new members of this family have recently been isolated:
IRS5
/Dok4 and IRS6/Dok5. This study examines the expression of
IRS5
/
DOK4
in a panel of lung cancer cell lines and tumor specimens. The results demonstrate that expression of
IRS5
/
DOK4
is frequently altered with both elevated and decreased expression in non-small-cell lung cancer (NSCLC) tumor specimens. The altered expression of
IRS5
/
DOK4
observed in tumor samples is not due to aberrant methylation. In vitro cell culture studies demonstrate that treatment of NSCLC cell lines with the histone deacetylase inhibitor trichostatin A (TSA) upregulates
IRS5
/
DOK4
. This finding indicates that expression is regulated epigenetically at the level of chromatin remodeling. Chromatin immunoprecipitation experiments confirm that the
IRS5
/
DOK4
promoter has enhanced histone hyperacetylation following treatments with TSA. Finally, hypoxia was demonstrated to downregulate
IRS5
/
DOK4
expression. This expression was restored by TSA. The clinical relevance of altered
IRS5
/
DOK4
expression in NSCLC requires further evaluation.
Clin
Lung Cancer
2008 Nov
PMID:Transcriptional regulation of IRS5/DOK4 expression in non-small-cell lung cancer cells. 1907 20